Acipimox

Acipimox is an antilipolytic agent. It inhibits lipolysis induced by noradrenaline and theophylline in rat epididymal adipocytes when used at a concentration of 1 µM. Acipimox (3 and 12 mg/kg, p.o.) decreases plasma free fatty acid levels in rats. It reduces plasma fatty acid concentration, the number of atherosclerotic plaques, and matrixmetalloproteinase-2 (MMP-2) activity in ApoE-/- mice fed a palmitate-rich diet. Acipimox also reduces fasting blood glucose and plasma insulin levels as well as plasma free fatty acid and triglyceride levels in a rat model of diabetes induced by streptozotocin (Cay-13104). Formulations containing acipimox have been used in the treatment of hyperlipidemia in patients with non-insulin-dependent diabetes.Formal Name: 5-methyl-2-pyrazinecarboxylic acid, 4-oxide. CAS Number: 51037-30-0. Molecular Formula: C6H6N2O3. Formula Weight: 154.1. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: slightly soluble, PBS (pH 7.2): 5 mg/ml. lambdamax: 233, 276 nm. SMILES: CC1=CN=C(C(O)=O)C=[N+]1[O-]. InChi Code: InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10). InChi Key: DJQOOSBJCLSSEY-UHFFFAOYSA-N.